Clinical features, pathophysiology and management of fatal familial insomnia

Veronica Redaelli, Fabrizio Tagliavini, Fabio Moda

Research output: Contribution to journalReview article

Abstract

Introduction: Fatal Familial Insomnia (FFI) is an inherited prion disorder caused by a point mutation at codon 178 of the PRNP gene, resulting in aspartic acid to asparagine substitution (D178N) in coupling phase with methionine at position 129. The disease is associated with sleep alterations, autonomic dysfunctions, loss of weight and motor signs. After symptoms onset, the disease usually leads to death within 2 years and no treatments are available at present. Areas covered: This review focuses on classical and innovative aspects of FFI, with special emphasis on recent indications that infectious prion are not only confined to the central nervous system but can be detected in peripheral tissues of diseased patients. Expert opinion: Although FFI can be genetically diagnosed, the ability of innovative techniques to specifically detect minute amount of infectious prion in peripheral tissues (such as the olfactory mucosa) is of fundamental importance for disease monitoring and to evaluate the efficacy of specific treatments to interfere with disease progression. Overall, the ability of these techniques to mimic the process of prion propagation in vitro can be exploited to perform preliminary high throughput screenings of compounds in order to select the most effective for FFI treatment.

Original languageEnglish
Pages (from-to)397-404
Number of pages8
JournalExpert Opinion on Orphan Drugs
Volume5
Issue number5
DOIs
Publication statusPublished - May 4 2017

Fingerprint

Fatal Familial Insomnia
Prions
Aptitude
Olfactory Mucosa
Asparagine
Expert Testimony
Point Mutation
Aspartic Acid
Codon
Methionine
Disease Progression
Weight Loss
Sleep
Central Nervous System
Therapeutics
Genes

Keywords

  • doxycycline
  • FFI
  • neurodegeneration
  • PMCA
  • prion

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Clinical features, pathophysiology and management of fatal familial insomnia. / Redaelli, Veronica; Tagliavini, Fabrizio; Moda, Fabio.

In: Expert Opinion on Orphan Drugs, Vol. 5, No. 5, 04.05.2017, p. 397-404.

Research output: Contribution to journalReview article

Redaelli, Veronica ; Tagliavini, Fabrizio ; Moda, Fabio. / Clinical features, pathophysiology and management of fatal familial insomnia. In: Expert Opinion on Orphan Drugs. 2017 ; Vol. 5, No. 5. pp. 397-404.
@article{c15122d042cf4328a43d216aa20827a5,
title = "Clinical features, pathophysiology and management of fatal familial insomnia",
abstract = "Introduction: Fatal Familial Insomnia (FFI) is an inherited prion disorder caused by a point mutation at codon 178 of the PRNP gene, resulting in aspartic acid to asparagine substitution (D178N) in coupling phase with methionine at position 129. The disease is associated with sleep alterations, autonomic dysfunctions, loss of weight and motor signs. After symptoms onset, the disease usually leads to death within 2 years and no treatments are available at present. Areas covered: This review focuses on classical and innovative aspects of FFI, with special emphasis on recent indications that infectious prion are not only confined to the central nervous system but can be detected in peripheral tissues of diseased patients. Expert opinion: Although FFI can be genetically diagnosed, the ability of innovative techniques to specifically detect minute amount of infectious prion in peripheral tissues (such as the olfactory mucosa) is of fundamental importance for disease monitoring and to evaluate the efficacy of specific treatments to interfere with disease progression. Overall, the ability of these techniques to mimic the process of prion propagation in vitro can be exploited to perform preliminary high throughput screenings of compounds in order to select the most effective for FFI treatment.",
keywords = "doxycycline, FFI, neurodegeneration, PMCA, prion",
author = "Veronica Redaelli and Fabrizio Tagliavini and Fabio Moda",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/21678707.2017.1311251",
language = "English",
volume = "5",
pages = "397--404",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Clinical features, pathophysiology and management of fatal familial insomnia

AU - Redaelli, Veronica

AU - Tagliavini, Fabrizio

AU - Moda, Fabio

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Fatal Familial Insomnia (FFI) is an inherited prion disorder caused by a point mutation at codon 178 of the PRNP gene, resulting in aspartic acid to asparagine substitution (D178N) in coupling phase with methionine at position 129. The disease is associated with sleep alterations, autonomic dysfunctions, loss of weight and motor signs. After symptoms onset, the disease usually leads to death within 2 years and no treatments are available at present. Areas covered: This review focuses on classical and innovative aspects of FFI, with special emphasis on recent indications that infectious prion are not only confined to the central nervous system but can be detected in peripheral tissues of diseased patients. Expert opinion: Although FFI can be genetically diagnosed, the ability of innovative techniques to specifically detect minute amount of infectious prion in peripheral tissues (such as the olfactory mucosa) is of fundamental importance for disease monitoring and to evaluate the efficacy of specific treatments to interfere with disease progression. Overall, the ability of these techniques to mimic the process of prion propagation in vitro can be exploited to perform preliminary high throughput screenings of compounds in order to select the most effective for FFI treatment.

AB - Introduction: Fatal Familial Insomnia (FFI) is an inherited prion disorder caused by a point mutation at codon 178 of the PRNP gene, resulting in aspartic acid to asparagine substitution (D178N) in coupling phase with methionine at position 129. The disease is associated with sleep alterations, autonomic dysfunctions, loss of weight and motor signs. After symptoms onset, the disease usually leads to death within 2 years and no treatments are available at present. Areas covered: This review focuses on classical and innovative aspects of FFI, with special emphasis on recent indications that infectious prion are not only confined to the central nervous system but can be detected in peripheral tissues of diseased patients. Expert opinion: Although FFI can be genetically diagnosed, the ability of innovative techniques to specifically detect minute amount of infectious prion in peripheral tissues (such as the olfactory mucosa) is of fundamental importance for disease monitoring and to evaluate the efficacy of specific treatments to interfere with disease progression. Overall, the ability of these techniques to mimic the process of prion propagation in vitro can be exploited to perform preliminary high throughput screenings of compounds in order to select the most effective for FFI treatment.

KW - doxycycline

KW - FFI

KW - neurodegeneration

KW - PMCA

KW - prion

UR - http://www.scopus.com/inward/record.url?scp=85018276568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018276568&partnerID=8YFLogxK

U2 - 10.1080/21678707.2017.1311251

DO - 10.1080/21678707.2017.1311251

M3 - Review article

AN - SCOPUS:85018276568

VL - 5

SP - 397

EP - 404

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 5

ER -